Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  NY-ESO-1 peptide vaccine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-20 of 20 for your search:
Start Over
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-1391, NCT01079741
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000068403, NCI-01-C-0032, NCI-2390, 2390, NCT00020397
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000354491, NCI-04-C-0104, NCI-6233, 6233, NCT00079144
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-009, NCT00199901
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2002-013, CTN Trial No.: 2007/123, CTN-Protocol# LUD2002-013AMEND, NCT00518206
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000318803, MSKCC-03034, LUDWIG-LUD2002-014, NCT00066729
Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000329920, MSKCC-03047, LUDWIG-LUD2002-004, NCT00070070
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2002-005, NCT00106158
Immunotherapy of Stage III/IV Melanoma Patients
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD 2001-003, NCT00112242
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 04-53, LUD2004-006, NCT00142454
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-022;NYU05-120;CUMC9147, NCT00299728
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-1390, NCT00821652
Decitabine, Vaccine Therapy, and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000640517, RPCI-I-127008, I 127008, NCT00887796
CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 05-140, 1R01CA112198-01, NCT00819806
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MCC-15383, 106566, NCI-P-8215, NCT01008527
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: MCC-15400, NCI-P-7997, CA209-006/007, 10-15526-99-01, 7997, NCT01176461
Start Over